Alterations of receptor-type tyrosine kinases (RTK) are frequent in human cancers. They can result from translocation, mutation or amplification. The ERBB2 RTK is encoded by a gene that is amplified in about 20% breast cancers. The question is: why is this RTK specifically subjected to this type of alteration? We propose that ERBB2 gene amplification is used to overcome repression of its expression by sequence-specific transcription factors. © 2009 Birnbaum et al; licensee BioMed Central Ltd.
CITATION STYLE
Birnbaum, D., Sircoulomb, F., & Imbert, J. (2009). A reason why the ERBB2 gene is amplified and not mutated in breast cancer. Cancer Cell International, 9. https://doi.org/10.1186/1475-2867-9-5
Mendeley helps you to discover research relevant for your work.